• Explore /
  • Poster
  • / A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.

A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.

Abstract Poster

Authors

null

Zhi Peng

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China

Zhi Peng , Tianshu Liu , Jia Wei , Airong Wang , Yifu He , Liuzhong Yang , Xizhi Zhang , Nan-Feng Fan , Suxia Luo , Jifang Gong , Zhen Li , Kangsheng Gu , Jin Wei LU , Jianming Xu , Qingxia Fan , Liangming Zhang , Jianmin Fang , Yi Ba , Lin Shen , Rui-hua Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03556345

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4560)

DOI

10.1200/JCO.2020.38.15_suppl.4560

Abstract #

4560

Poster Bd #

168

Abstract Disclosures

Similar Posters

First Author: Shubham Pant

First Author: Daisuke Takahari

First Author: Tamta Makharadze

First Author: Kazuomi Ueshima